Evaluating preference weights for the Asthma Symptom Utility Index (ASUI) across countries
- PDF / 526,295 Bytes
- 10 Pages / 610 x 792 pts Page_size
- 45 Downloads / 169 Views
Open Access
Research
Evaluating preference weights for the Asthma Symptom Utility Index (ASUI) across countries Emuella M Flood1, Erwin De Cock1, Ann-Christin Mörk2 and Dennis A Revicki*1 Address: 1Center for Health Outcomes Research, United BioSource Corporation, Bethesda, MD, United States, London, UK and 2Formerly of AstraZeneca, Lund, Sweden Email: Emuella M Flood - [email protected]; Erwin De Cock - [email protected]; AnnChristin Mörk - [email protected]; Dennis A Revicki* - [email protected] * Corresponding author
Published: 15 August 2006 Health and Quality of Life Outcomes 2006, 4:51
doi:10.1186/1477-7525-4-51
Received: 13 June 2006 Accepted: 15 August 2006
This article is available from: http://www.hqlo.com/content/4/1/51 © 2006 Flood et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract Background: The Asthma Symptom Utility Index (ASUI) is a preference-based outcome measure used in US clinical trials and cost-effectiveness studies for asthma. This study evaluated ASUI preference weights in Europe to determine whether the multi-attribute utility function, based on preferences from a US population, is generalizable across countries. Methods: Data were collected from ninety asthma patients from Italy, France, and the United Kingdom using the Asthma Control Questionnaire, the Asthma Quality of Life Questionnaire, and the ASUI. Subjects rated their preferences for 10 asthma health states using a visual analogue scale (VAS) and a standard gamble (SG) interview. Results: All multi-symptom states showed statistically significant differences (p < 0.001) between countries in mean VAS scores. Mean SG utility scores between the US and France and the US and Italy demonstrated statistically significant differences (p < 0.001) for three states: severe wheeze; moderate cough and wheeze; and moderate cough and dyspnea. Because of these differences, the multi-attribute utility functions derived within countries were somewhat different. Despite these differences, country-specific algorithms captured a similar rank ordering of patients by disease severity, were strongly correlated (r = 0.971 to 0.995), and demonstrated similar relationships with symptom and AQLQ scores. Conclusion: Results of this study suggest that the ASUI may be a complementary patient-reported outcome for clinical studies and may be useful for applications in cost-effectiveness studies comparing different asthma treatments.
Background Patient-reported outcomes, such as patient perceptions of symptom frequency and severity and their health-related quality of life (HRQL) are important for clinical management and for evaluating new treatments for asthma [1].
These patient based outcomes have been used to evaluate pharmacologic and
Data Loading...
